Escherichia coli genomic DNA at CRISPR-Cas protospacer targets (E. coli CRISPR target DNA)

Escherichia coli genomic DNA at CRISPR-Cas protospacer targets refers to specific nucleotide sequences within the E. coli genome that are recognized by guide RNAs (gRNAs) and subsequently cleaved by Cas nucleases (Gomaa et al., 2014, mBio). These sites serve as the physical target for CRISPR-Cas effector proteins, such as Cas9 or Cas3, which induce sequence-specific double-strand breaks or processive DNA degradation (Beisel et al., 2014, Nature Communications). In a therapeutic context, these targets are selected within essential genes or virulence factors to ensure that cleavage results in bacterial cell death, providing a mechanism for highly selective 'programmable' antimicrobials (Citorik et al., 2014, Nature Biotechnology). Clinical-stage candidates like SNIPR-001 and LBP-EC01 utilize engineered bacteriophages to deliver CRISPR-Cas systems that target these genomic sites in pathogenic E. coli strains (SNIPR Biome, 2023; Locus Biosciences, 2024). This approach aims to treat infections, such as urinary tract infections or bacteremia, while minimizing collateral damage to the commensal microbiota (Knott & Doudna, 2018, Science). Safety considerations include the potential for off-target effects in the human genome or beneficial bacteria and the emergence of resistance through target site mutations (Fu et al., 2013, Nature Biotechnology).

Other names

E. coli genomic DNACRISPR-Cas target sequenceBacterial protospacer DNAE. coli protospacer

Sequence-specific DNA cleavage and degradation mediated by CRISPR-Cas effector proteins (e.g., Cas3, Cas9), leading to bacterial cell death.